Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the expiry in 2006 of patents for Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will dramatically curb growth in the market to treat dyslipidemia.

A new Pharmacor report entitled Dyslipidemia finds that the patent expiries of Zocor and Pravachol will trigger a shift in prescribing behavior as many HMOs remove the branded equivalents from their formularies. The report forecasts that widespread generics substitution will offset the impact of new product launches and will cause annual sales in the dyslipidemia market to grow by only 0.1% annually through 2014.

"In Europe, the transfer of patient share from branded statins to generic simvastatin is already a prominent dynamic, and we expect a similar trend in the United States," said Nikhil Mehta, analyst at Decision Resources, Inc. "Although new therapies that target low high-density lipoprotein levels will address an important unmet need and add to market value, experts in the field remain uncertain as to whether their mechanisms of action will indeed confer clinical benefit."

About Dyslipidemia

The term dyslipidemia refers to any abnormality in circulating lipid levels. This abnormality can include an elevation in any one of the lipid subfractions of low-density lipoprotein, very-low-density lipoprotein, or triglyceride. The term additionally encompasses any reduction in the circulating levels of high-density lipoprotein.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Illinois Medicaid Cuts Drive Out Humana and UnitedHealth Group, According to HealthLeaders-InterStudy

View Now